Stock Taper
SCREENER COMPARE ANY 2 STOCKS
OTLK
OUTLOOK THERAPEUTICS, INC.
NASDAQ
$0.67
▲ UP 2.70% (0.02)

KEY STATISTICS

Market Cap$124.63 M
52w High$2.54
52w Low$0.16
Dividend Yield—
Frequency—
P/E-0.64
Volume6.35M
Shares Out.187.00M

COMPANY

LEADERSHIP

Robert Charles Jahr
CHIEF EXECUTIVE
Robert Charles Jahr

COMPENSATION 2026

Salary$475,000
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$1,170
Total$476,170

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 14, 2016
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
17

PRICE TARGET

Target High$4.00
Target Low$1.60
Target Median$2.80
Target Consensus$2.80

UPCOMING EARNINGS

DateDec 18, 2026
DayFriday
Rev. Est.$2.98M
DEC
18
FRI

SPLIT RECORD

DATETYPERATIO
2024-03-14Reverse1:20
2019-03-18Reverse1:8

PRICE

$0.67 ▲ UP 2.70% (+$0.02)
OVERLAYS
$0.65$0.66$0.68$0.699:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM0.67

About Outlook Therapeutics, Inc.

https://www.outlooktherapeutics.com ↗

Outlook Therapeutics, Inc. is a late-stage biopharma company developing monoclonal antibodies like ONS-5010 for ophthalmic diseases, with collaborations worldwide and a focus on wet age-related macular degeneration.

INDUSTRY

Biotechnology

A PRODUCT OUTLOOK THERAPEUTICS, INC. IS KNOWN FOR

ONS-5010 / LYTENAVA™ (bevacizumab-vikg)
ONS-5010 / LYTENAVA™ (bevacizumab-vikg)

An investigational ophthalmic bevacizumab formulation for wet AMD, currently under U.S. regulatory review and approved in the EU and UK.

COMPETITORS

COMPETITOR
EYPT COMPARE
KOD COMPARE
NVS COMPARE
REGN COMPARE
RGNX COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
11
LISTED HERE
1
RANKED BY POSITION SIZE
VTS.AX
0.00% · 3.1M

INSTITUTIONAL OWNERSHIP

SHARES OWNED
6.18%
HOLDERS
82
TOP 12 OF 82 · RANKED BY POSITION SIZE
Armistice Capital, LLC
4.2M sh · $857.77K
Schonfeld Strategic Advisors LLC
2.4M sh · $3.86M
Vanguard Group Inc
1.5M sh · $2.31M
Blackrock Inc.
663.5K sh · $4.9M
Geode Capital Management, LLC
603.6K sh · $124.23K
Blackrock, Inc.
477.5K sh · $98.26K
Commonwealth Equity Services, LLC
470.0K sh · $96.73K
Marshall Wace, Llp
298.5K sh · $471.56K
Warberg Asset Management LLC
275.0K sh · $56.38K
Renaissance Technologies LLC
255.2K sh · $52.51K
Nine Masts Capital Ltd
232.5K sh · $47.86K
Susquehanna International Group, Llp
211.4K sh · $224.11K

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
OFFICER: CHIEF FINANCIAL OFFICER
Lundquist Kevin Michael
Purchase · 500.0K shares
2026-09-01
★
Lundquist Kevin Michael
— · —
2026-09-01
★
DIRECTOR, 10 PERCENT OWNER:
Sukhtian Ghiath M.
Purchase · 2.5M shares
2026-08-12
★
DIRECTOR, OFFICER: CHIEF FINANCIAL OFFICER
KENYON LAWRENCE A
Purchase · 101.0K shares
2026-08-14

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
NEUTRAL 2
4 GRADES IN THE LAST 12 MONTHS
BTIG BUY HC Wainwright & Co. NEUTRAL Ascendiant Capital BUY Chardan Capital NEUTRAL

SECTORS PEERS

PEERPRICE
IPSC$2.13COMPARE
SPRB$57.54COMPARE
EQ$2.25COMPARE
OSTX$1.89COMPARE
CUE$27.56COMPARE
NRXP$3.44COMPARE
HOWL$0.95COMPARE
MDCX$0.18COMPARE